Akutbehandlung der Schizophrenie

• Literatur

• 1 Gaebel W, Falkai P. Hrsg. S2-Praxisleitlinie in Psychiatrie und Psychotherapie. Band 2. Behandlungsleitlinie Therapeutische Maßnahmen bei aggressivem Verhalten. Heidelberg: Springer; 2009
• 2 Gaebel W, Falkai P. Hrsg. S3-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff; 2006
• 3 Hasan A, Falkai P, Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1. Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318-378
• 4 Keshavan MS, Morris DW, Sweeney JA. et al. A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: the Schizo-Bipolar Scale. Schizophrenia Res 2011; 133: 250-254
• 5 Gründer G. Antipsychotika. In: Gründer G, Benkert O. Hrsg. Handbuch der Psychopharmakotherapie. Berlin, Heidelberg: Springer; 2012
• 6 Leucht S, Corves C, Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia. A meta-analysis. Lancet 2009; 373: 31-41
• 7 Jones PB, Barnes TRE, Davies L. et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch General Psychiatry 2006; 63: 1079-1087
• 8 Heres S, Hamann J, Mendel R. et al. Identifying the profile of optimal candidates for antipsychotic depot therapy. A cluster analysis. Progress Neuro-Psychopharmacol Biol Psychiatry 2008; 32: 1987-1993
• 9 Baandrup L, Gasse C, Jensen VD. et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010; 71: 103-108
• 10 Fleischhacker WW, Hofer A. Schizophrene Störungen. Klinische Psychopharmakotherapie. In: Gründer G, Benkert O. Hrsg. Handbuch der Psychopharmakotherapie. 2.. Aufl. Berlin, Heidelberg: Springer; 2012
• 11 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 8.. Aufl. Berlin, Heidelberg, New York: Springer; 2011
• 12 Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567-620
• 13 Rummel-Kluge C, Komossa K, Schwarz S. et al. Second-generation antipsychotic drugs and extrapyramidal side effects. A systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bull 2012; 38: 167-177
• 14 Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health-System Pharmacy 1997; 54: 2461-2477
• 15 Agid O, Kapur S, Arenovich T. et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60: 1228-1235
• 16 Kinon BJ, Chen L, Ascher-Svanum H. et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Res 2008; 102: 230-240
• 17 Hiemke C, Baumann P, Bergemann N. et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235
• 18 Donnelly L, Rathbone J, Adams CE. Haloperidol dose for the acute phase of schizophrenia. Cochrane database of systematic reviews 2013; 8: CD001951
• 19 Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50: 898-911
• 20 Chakos M, Lieberman J, Hoffman E. et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia. A review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526
• 21 Buchanan RW. Clozapine. Efficacy and safety. Schizophrenia Bull 1995; 21: 579-591
• 22 Müller MJ, Lange-Asschenfeldt C. Pharmakotherapie psychiatrischer Notfallsituationen. In: Gründer G, Benkert O. Hrsg. Handbuch der Psychopharmakotherapie. Berlin, Heidelberg: Springer; 2012
• 23 Georgieva I, Mulder CL, Wierdsma A. Patients’ preference and experiences of forced medication and seclusion. Psychiatric Quarterly 2012; 83: 1-13
• 24 Haddock G, Eisner E, Boone C. et al. An investigation of the implementation of NICE-recommended CBT interventions for people with schizophrenia. J Ment Health 2014; 23: 162-165
• 25 Kuipers E, Yesufu-Udechuku A, Taylor C. et al. Management of psychosis and schizophrenia in adults. Summary of updated NICE guidance. Br Med J 2014; 348: g1173
• 26 Klingberg S, Hesse K. Stationäre evidenzbasierte Psychotherapie bei Psychosen. Kognitiv-verhaltenstherapeutisches Praxismanual. 1.. Aufl. Stuttgart: Kohlhammer; 2014
• 27 DGPPN. S3-Leitlinie Psychosoziale Therapie bei schweren psychischen Erkrankungen. Heidelberg: Springer; 2013
• 28 Munz I, Ott M, Jahn H. et al. [Comparison of “home treatment” with traditional inpatient treatment in a mental hospital in rural southern Germany]. Psychiat Prax 2011; 38: 123-128